肿瘤浸润淋巴细胞：新希望。
Tumor-infiltrating lymphocytes: A new hope.
发表日期：2024 Aug 12
作者：
Amod A Sarnaik, Patrick Hwu, James J Mulé, Shari Pilon-Thomas
来源：
CANCER CELL
摘要：
肿瘤浸润淋巴细胞（TIL）可以从切除的肿瘤中大量扩增，并用作晚期恶性肿瘤的细胞治疗。 TIL 需要先进行预备性非清髓性化疗，然后进行简短的白细胞介素 2 疗程。在这里，我们回顾了 TIL 疗法的历史发展，并讨论了针对当前障碍的潜在解决方案，这些解决方案可能会为患有难治性晚期癌症的患者带来更广泛和更高的疗效。版权所有 © 2024 Elsevier Inc. 保留所有权利。
Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved efficacy for patients afflicted with treatment-refractory, advanced cancer.Copyright © 2024 Elsevier Inc. All rights reserved.